• Alnylam Pharmaceuticals Inc., of Cambridge, Mass., completed a Phase I trial of ALN-VSP, an RNAi therapeutic for solid tumors with liver involvement. Alnylam said the results demonstrated antitumor activity in addition to safety and tolerability. Multiple patients in the study achieved stable disease, and one achieved partial response with 70 percent tumor regression.

• Can-Fite BioPharma Ltd., of Petah-Tikva, Israel, began enrollment in a Phase II/III trial of its lead candidate, CF101, for psoriasis. The randomized, double-blind, controlled trial will compare two dose levels of CF101 with placebo. About 300 patients are expected to be enrolled at 17 sites in Europe, Israel and the U.S. The primary endpoints include the Physician's Global Assessment, body surface area involvement and PASI.